, Volume 27, Issue 11, pp 1071-1077
Date: 03 Apr 2007

A pravastatin dose-escalation study in systemic lupus erythematosus

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (±12.1%) and LDL by 24% (±17%), compared with 1.8% (±7.5%) and 2.6% (±8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.

Supported by NIH grants P60 AR47782, R0149880 and K24 AR052401, the Kirkland Scholar Fellowship, Arthritis Foundation/American College of Rheumatology Arthritis Investigator Award, Rheuminations and a 50th Anniversary Scholars in Medicine Award from Harvard Medical School.